GRI Bio, Inc. — Director's Dealing 2022

Jun 10, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vallon Pharmaceuticals, Inc. (VLON)
CIK: 0001824293
Period of Report: 2022-06-09

Reporting Person: Thorell Marella (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Stock Option (Right to Buy)	$0.51	A	7500	Acquired	2032-06-09	Common Stock (7500.0)	Direct

Footnotes

F1: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.